Found 108 clinical trials
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative Her2-Low Invasive Breast Cancer
by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative Her2-Low Invasive Breast Cancer
- 306 views
- 08 Nov, 2020
- 1 location
Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node
investigator propose a Non Inferiority Randomized Multicenter Phase III Trial of Axillary Node Dissection Versus no Axillary Node Dissection in Case of Positive Sentinel Lymph Node in Invasive Breast Cancer
- 0 views
- 24 Jan, 2021
- 1 location
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY)
The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.
- 33 views
- 09 Jul, 2022
- 6 locations
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
breast cancer. The hypothesis is that FFNP SUVmax from PET/MRI will correlate well against the semi-quantitative PR immunohistochemistry score.
- 0 views
- 31 Jan, 2022
- 1 location
EMDR Psychotherapy of Anxious-depressive Symptoms for Women That Present an Invasive Breast Cancer : a Randomised Controlled Trial (PSYCANCER)
The study will consist in an evaluation of the EMDR (Eye Movement Desensitization and Reprocessing) psychotherapy in the context on invasive primitive breast cancer. EMDR could then allow the affected patients to readjust their point of view on the pathology and thus promote more adapted behaviors or additional resources to …
- 0 views
- 16 Oct, 2022
- 1 location
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0
- 0 views
- 19 Apr, 2022
- 1 location
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)
-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
- 8 views
- 20 Jun, 2022
- 43 locations
![[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma](/media/imagery/259550.svg)
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
FES PET/CT imaging for invasive lobular cancer
- 0 views
- 14 Jul, 2022
- 1 location
Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
Locally advanced breast cancer has high-risk local regional recurrence after surgery. Radiotherapy could reduce the local regional recurrence and improve disease free survival and overall survival. Regional lymph node irradiation is the important part of breast cancer radiotherapy. However, there are some controversies about regional lymph node delineation, especially the …
- 0 views
- 01 Nov, 2021
- 1 location
Omission of Breast Surgery for Predicted Pathologic Complete Response Patients With MRI and Vacuum-assisted bIopsy in Breast Cancer After Neoadjuvant Chemotherapy a Multicenter, Single-arm, Non-inferiority Trial (OPTIMIST)
A prospective, multicenter, single-arm non-inferiority trial to demonstrate that breast cancer patients who are predicted to have a pathologic complete response on MRI and vacuum-assisted biopsy after neoadjuvant chemotherapy, and are omitted breast surgery have a non-inferior 5-year disease-free survival compared to those who had received breast surgery.
- 0 views
- 28 Oct, 2022
- 1 location